Bone Marrow Transplantation for Cancer: An Overview

  • D. D. Hurd
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 132)

Abstract

Although allogeneic bone marrow transplantation has been attempted for over 50 years (Bortin 1970), it was not until 1968 that the first successful transplant was achieved in a child with an immunodeficiency syndrome (Gatti et al. 1968). Since that time, allogeneic, and more recently autologous, transplantation has grown repidly as a means of treating a variety of malignant and nonmalignant disorders. In a recent survey conducted by the International Bone Marrow Transplant Registry (IBMTR), data from 342 institutions in 47 countries revealed that 14745 patients had been treated with either allogeneic or syngeneic transplants during the years 1988–1990 (Bortin et al. 1992). Overall, it is estimated that over 32500 allogeneic or syngeneic transplants have been performed worldwide since the first successful transplant.

Keywords

Hepatitis Lymphoma Leukemia Oncol Diarrhea 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Advisory Committee of the International Autologous Bone Marrow Transplant Registry (1989) Autologous bone marrow transplants: different indications in Europe and America. Lancet ii: 317–318Google Scholar
  2. Ash R, Horowitz MM, Gale RP, van Bekkum DW, Casper JY, Gordon-Smith EC, Henslee-Downey PJ, Kolb JH, Lowenberg B, Masaoka T, McGlave PB, Rimm AA, Ringdén O, van Rood JJ, Sondel PM, Vowels Mr, Bortin MM (1991) Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T-cell depletion. Bone Marrow Transplant 7: 443–452PubMedGoogle Scholar
  3. Berenson RJ, Bensinger WI, Hill RS, Andrews RG, Garcia-Lopez J, Kalamasz DF, Still BJ, Spitzer G, Buckner CD, Bernstein ID, Thomas ED (1991) Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 77: 1717–1722PubMedGoogle Scholar
  4. Bortin MM (1970) A compendium of reported human bone marrow transplants. Transplantation 9: 571–587PubMedCrossRefGoogle Scholar
  5. Bortin MM, Horowitz MM, Rimm AA (1992) Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988–1990 survey. Ann Intern Med 116: 505–512PubMedGoogle Scholar
  6. Ferrara JLM, Deeg HJ (1991) Mechanisms of disease: graft versus host disease. N Engl J Med 324: 667–674PubMedCrossRefGoogle Scholar
  7. Frei E III, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585–594PubMedCrossRefGoogle Scholar
  8. Gatti RA, Allen HD, Meuwissen HJ, Hong R, Good RA (1968) Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet ii: 1366–1369CrossRefGoogle Scholar
  9. Gorin NC, Aegerter P, Auvert B, Meloini G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D, Löwenberg R, Verdonck LF, de Planque M, Hermans J, Helbig W, Porcellini A, Rizzoli V, Alesandrino EP, Franklin IM, Reifiers J, Collesslli P, Goldman JM (1990) Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 75: 1606–1614PubMedGoogle Scholar
  10. Gulati SC, Lemoli RM, Acaba L, Igaraeshi T, Wasserheit C, Fraig M (1992) Purging in autologous and allogeneic bone marrow transplantation. Curr Op in Oncol 4: 264–278CrossRefGoogle Scholar
  11. Hansen JA, Choo YS, Geraghty DE, Mickelson E (1990) The HLA system in clinical marrow transplantation. Hematol Oncol Clin North Am 4: 507–515PubMedGoogle Scholar
  12. Hurd DD (1987) Allogeneic and autologous bone marrow transplantation for acute nonlymphocytic leukemia. Semin Oncol 14: 407–415PubMedGoogle Scholar
  13. Nemunaitis J, Rabinowe SN, Singer Jw, Bierman Pj, Vose Jm, Freedman AS, Onetto N, Gillis S, Oette D, Gold M, Duckner CD, Hansen JA, Ritz J, Applebaum FR, Armitage JO, Nadler LM (1991) Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324: 1773–1778PubMedCrossRefGoogle Scholar
  14. Stroncek DF, Fautsch S, Lasky L, Hurd DD, Ramsay N, McCullough JJ (1991) Adverse reactions in patients transfused with cryopreserved marrow. Transfusion 31: 521–526PubMedCrossRefGoogle Scholar
  15. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Flournoy N, Goodell BW, Hickman HO, Lerner KG, Neiman PE, Sale GE, Śanders JE, Singer J, Stevens M, Storb R, Weiden PL (1977) One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 49: 511–533PubMedGoogle Scholar
  16. Thomas ED, Buckner CD, Clift RA, Fefer A, Johnson LF, Neiman PE, Sale GE, Sanders JE, Singer J, Shulman H, Storb R, Weiden PL (1979) Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 301: 597–599PubMedCrossRefGoogle Scholar
  17. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant Team (1981) Antileukemic effect of graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529–1533PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • D. D. Hurd
    • 1
  1. 1.Comprehensive Cancer Center of Wake Forest UniversityBowman Gray School of MedicineWinston SalemUSA

Personalised recommendations